CAAS Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-11,900
Closed -$115K – 1394
2020
Q4
$115K Hold
11,900
– – ﹤0.01% 787
2020
Q3
$107K Hold
11,900
– – ﹤0.01% 455
2020
Q2
$147K Sell
11,900
-579,400
-98% -$6.55M ﹤0.01% 377
2020
Q1
$5.31M Buy
+591,300
New +$6.06M 0.55% 42

Other funds holding TEVA

CAAS Capital Management's TEVA Position: Q2 2020 in Review

CAAS Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2020, closing a stake of 106,400 shares — an estimated $1.2M sold.

CAAS Capital Management first reported a position in TEVA in Q1 2020 and held it in 1 quarter. The position peaked at $955K in Q1 2020. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

  • CAAS Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2020 after selling out during the quarter.
  • CAAS Capital Management sold 106,400 Teva Pharmaceutical Industries Limited shares in Q2 2020, an estimated $1.2M.
  • CAAS Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q1 2020 and held it in 1 quarter.
  • CAAS Capital Management's Teva Pharmaceutical Industries Limited position peaked at $955K in Q1 2020.
  • 456 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2020.

Based on CAAS Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.